Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


biocrea expands management team

This article was originally published in Scrip

Executive Summary

German CNS therapeutics company, biocrea GmbH, a management buy-out from Finland's Biotie Therapies, has expanded its management team by appointing Dr Martin Gunthorpe as Chief Scientific Officer, Mr Viktor Viehweg to the position of Chief Financial Officer, and Professor Simon Ward to Executive Vice President Chemistry & Development. Dr Gunthorpe joins biocrea from GlaxoSmithKline, where he was Head of Electrophysiology and Project Leader in the Neurosciences Centre of Excellence for Drug Discovery. Professor Ward also joins biocrea from GSK, where he has been Assistant Director and a member of business unit & chemistry leadership teams, he also holds the Chair of Medicinal Chemistry at the University of Sussex, UK. Mr Viehweg was most recently Head of Corporate Strategy at Moscow-based Sibur Ltd.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts